Mineralys Therapeutics, Inc. (MLYS)
Healthcare
Biotechnology
25.50 $
-2.6%
vs. previous close
Closing price · As of: 31. Jul 2026
Mineralys Therapeutics, Inc. (MLYS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -142 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -2.5 | -15 | -29 | -81 | -166 | -142 | |
| – | – | – | 0.0 | 0.0 | 0.1 | |
| 0.0 | 0.1 | 0.5 | 5.1 | 11 | 19 | |
| 0.5 | 0.8 | -0.2 | – | – | – | |
| 0.5 | 4.1 | 0.8 | -7.5 | 9.5 | 2.7 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | |
| -22 | -22 | -22 | -160 | 115 | -390 | |
| 3.8 | – | – | – | – | – | |
| 0.0 | – | -1.6 | 0.1 | 0.2 | 0.2 | |
| 3.9 | 0.0 | – | – | – | – | |
| 3.8 | 24 | 128 | 203 | 116 | 591 | |
| 1.4 | 9.3 | 77 | -38 | 65 | 59 | |
| -2.5 | -15 | -29 | -81 | -166 | -142 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.